Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KITE-197 in Relapsed or Refractory Large B-cell Lymphoma
NCT06079164Phase 1Active, not recruiting
- Sponsor
- Kite Pharma
- Start
- Nov 2023
- Primary completion
- Nov 2026
- Modality
- CAR-T Cells
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of KITE-197 in Diffuse Large B-Cell Lymphoma (DLBCL), sponsored by Kite Pharma. Primary endpoints: Percentage of Participants Experiencing any Dose-limiting Toxicities at 28 days and Complete Remission Rate at 24 months. Started Nov 2023; status: active, not recruiting.
02
Drugs
KITE-197
03
Conditions
Diffuse Large B-Cell Lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06079164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06079164.